Infectious Disease

Individuals 6 months and older should receive updated COVID-19 and influenza vaccines for the 2024-2025 respiratory virus season, the agency recommended.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The investigational combination vaccine elicited higher immune responses vs licensed comparator vaccines in 2 independent age groups, the company said.

GSK announced today approval by the US FDA of a label expansion for the adjuvanted RSV vaccine that adds adults aged 50 to 59 years who are at elevated risk for RSV disease to the vaccine’s current indication.

The over-the-counter antigen test, for use at home or at point of care, discriminates between SARS-CoV-2 and influenza A and B in 15 minutes.

Your daily dose of the clinical news you may have missed.

Data presented at ACOG 2024 suggest SARS-CoV-2 infection early in pregnancy can lead to a higher likelihood of preeclampsia, as well as more severe disease.

Sipavibart met both dual primary endpoints in the SUPERNOVA phase 3 trial.

Get a quick overview of recommendations for preventive health services and screenings focused on the unique needs of women across the lifespan.

Details on educational gaps, vaccination rates, and the importance of an open dialogue between patients and clinicians, here.

While Moderna expects mRNA-1345 to be approved later this month, the company cites FDA administrative constraints as reason for delay.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

In STRIDE 10, V116 was superior to PPSV23 in adults aged ≥50 years and naive to pneumococcal vaccine for 8 of 9 serotypes unique to Merck's investigational shot.

Your daily dose of the clinical news you may have missed.

Pivmecillinam is an aminopenicillin, a class of beta-lactam antibiotics with a mechanism of action that may help reduce rising levels of antibiotic resistance.

Researchers found that the COVID-19 booster dose elicited a 71%-84% increase in the median anti-spike half-life over that of the primary series.

Vaccine efficacy remained high at 82% at year 11 following vaccination, according to new long-term data.

Your daily dose of the clinical news you may have missed.

The FDA expects to take action on the GSK BLA for its pentavalent MenB vaccine by February 14, 2025.

In adults hospitalized with RSV, odds of severe outcomes, including death, were much higher than for those admitted for, but vaccinated against, COVID-19, flu.

Investigators found vaccine uptake of 41% among unvaccinated individuals who were part of a messaging intervention in the emergency department.

Your daily dose of the clinical news you may have missed.

Ravi Jhaveri, MD, provides an overview of AstraZeneca's FluMist Quadrivalent vaccine and discusses why it could help increase vaccination rates.

New research highlights another benefit of COVID-19 vaccination, reported researchers.

Long COVID affects approximately 20 million people in the US and that number may be conservative. Here, a snapshot, through the fog, of the route they are on.

The novel 21-valent pneumococcal vaccine remains on track for the FDA PDUFA date of June 17, 2024; Merck adds this new data to the body of positive evidence.

Measles cases are edging up in the US again as MMR vaccination rates continue to decline. Have parents forgotten the Ohio outbreak of 2022? Have you? Find out, here.

The updated guidelines reflect the progress made in protecting against severe illness from COVID-19, said CDC Director Mandy Cohen, MD, MPH.